Evidence map›Paper›PMID 24231349›Full record

ArticleThe Journal of clinical investigation2013

Balancing GRK2 and EPAC1 levels prevents and relieves chronic pain.

Huijing Wang, Cobi J Heijnen, Cindy T J van Velthoven, Hanneke L D M Willemen, Yoshihiro Ishikawa, Xinna Zhang, Anil K Sood, Anne Vroon, Niels Eijkelkamp, Annemieke Kavelaars

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 96 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Role of EPAC1 in chronic pain.Biochemistry and biophysics reports · 2024
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 4 countries.

Huijing Wang
Cobi J Heijnen
Cindy T J van Velthoven
Hanneke L D M Willemen
Yoshihiro Ishikawa
Xinna Zhang
Anil K Sood
Anne Vroon
Niels Eijkelkamp
Annemieke Kavelaars
University Medical Center Utrecht · NLThe University of Texas MD Anderson Cancer Center · USYokohama City University · JP

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Neuroimmune Mechanisms of Recovery from Comorbid Depression and Chronic PainR01NS073939 · NINDS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DANTZER, ROBERT, HEIJNEN, COBI J · 2011 to 2020
$4.0M
A novel molecular switch regulating transition from acute to chronic pain.R01NS074999 · NINDS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KAVELAARS, ANNEMIEKE · 2011 to 2015
$1.7M
NCI NIH HHS P30 CA016672NINDS NIH HHS R01 NS073939NINDS NIH HHS R01NS073939NINDS NIH HHS R01 NS074999NINDS NIH HHS R01NS074999
6 · The paper itself

Abstract

Chronic pain is a major clinical problem, yet the mechanisms underlying the transition from acute to chronic pain remain poorly understood. In mice, reduced expression of GPCR kinase 2 (GRK2) in nociceptors promotes cAMP signaling to the guanine nucleotide exchange factor EPAC1 and prolongs the PGE2-induced increase in pain sensitivity (hyperalgesia). Here we hypothesized that reduction of GRK2 or increased EPAC1 in dorsal root ganglion (DRG) neurons would promote the transition to chronic pain. We used 2 mouse models of hyperalgesic priming in which the transition from acute to chronic PGE2-induced hyperalgesia occurs. Hyperalgesic priming with carrageenan induced a sustained decrease in nociceptor GRK2, whereas priming with the PKCε agonist ΨεRACK increased DRG EPAC1. When either GRK2 was increased in vivo by viral-based gene transfer or EPAC1 was decreased in vivo, as was the case for mice heterozygous for Epac1 or mice treated with Epac1 antisense oligodeoxynucleotides, chronic PGE2-induced hyperalgesia development was prevented in the 2 priming models. Using the CFA model of chronic inflammatory pain, we found that increasing GRK2 or decreasing EPAC1 inhibited chronic hyperalgesia. Our data suggest that therapies targeted at balancing nociceptor GRK2 and EPAC1 levels have promise for the prevention and treatment of chronic pain.

Indexed as

AnimalsCarrageenanCattleChronic PainCyclic AMPDinoprostoneFemaleGanglia, SpinalGene Expression RegulationGene SilencingGenetic TherapyG-Protein-Coupled Receptor Kinase 2Guanine Nucleotide Exchange FactorsHindlimbHyperalgesiaInjections, SpinalCarrageenanCyclic AMPDinoprostoneEpac protein, mouseG-Protein-Coupled Receptor Kinase 2GRK2 protein, mouseGuanine Nucleotide Exchange FactorsHis-Asp-Ala-Pro-Ile-Gly-Tyr-AspOligonucleotides, AntisenseOligopeptidesRecombinant Fusion Proteins

Identifiers

PMID24231349
PMCPMC3859388
OpenAlexW1994317895

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.